A Multicentered Prospective Cohort Study of Chinese IBD Patients
Conditions: Ulcerative Colitis; Crohn Disease Interventions: Drug: Infliximab; Drug: Vedolizumab; Drug: Ustekinumab; Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine) Sponsor: Peking Union Medical College Hospital Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials